BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 29394256)

  • 1. The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression.
    Coulibaly A; Haas A; Steinmann S; Jakobs A; Schmidt TJ; Klempnauer KH
    PLoS One; 2018; 13(2):e0190934. PubMed ID: 29394256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Products with Antitumor Potential Targeting the MYB-C/EBPβ-p300 Transcription Module.
    Schmidt TJ; Klempnauer KH
    Molecules; 2022 Mar; 27(7):. PubMed ID: 35408476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction.
    Uttarkar S; Dassé E; Coulibaly A; Steinmann S; Jakobs A; Schomburg C; Trentmann A; Jose J; Schlenke P; Berdel WE; Schmidt TJ; Müller-Tidow C; Frampton J; Klempnauer KH
    Blood; 2016 Mar; 127(9):1173-82. PubMed ID: 26631113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C/EBPβ sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module.
    Klempnauer KH
    Exp Hematol; 2022 Apr; 108():8-15. PubMed ID: 35032593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells.
    Uttarkar S; Piontek T; Dukare S; Schomburg C; Schlenke P; Berdel WE; Müller-Tidow C; Schmidt TJ; Klempnauer KH
    Mol Cancer Ther; 2016 Dec; 15(12):2905-2915. PubMed ID: 27707899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Helenalin Acetate, a Natural Sesquiterpene Lactone with Anti-inflammatory and Anti-cancer Activity, Disrupts the Cooperation of CCAAT Box/Enhancer-binding Protein β (C/EBPβ) and Co-activator p300.
    Jakobs A; Steinmann S; Henrich SM; Schmidt TJ; Klempnauer KH
    J Biol Chem; 2016 Dec; 291(50):26098-26108. PubMed ID: 27803164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Withaferin A, a natural compound with anti-tumor activity, is a potent inhibitor of transcription factor C/EBPβ.
    Falkenberg KD; Jakobs A; Matern JC; Dörner W; Uttarkar S; Trentmann A; Steinmann S; Coulibaly A; Schomburg C; Mootz HD; Schmidt TJ; Klempnauer KH
    Biochim Biophys Acta Mol Cell Res; 2017 Jul; 1864(7):1349-1358. PubMed ID: 28476645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C/EBPβ is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia.
    Yusenko MV; Trentmann A; Casolari DA; Abdel Ghani L; Lenz M; Horn M; Dörner W; Klempnauer S; Mootz HD; Arteaga MF; Mikesch JH; D'Andrea RJ; Gonda TJ; Müller-Tidow C; Schmidt TJ; Klempnauer KH
    Oncogene; 2021 Jul; 40(29):4746-4758. PubMed ID: 33958723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations in multiple domains of c-Myb disrupt interaction with CBP/p300 and abrogate myeloid transforming ability.
    Pattabiraman DR; Sun J; Dowhan DH; Ishii S; Gonda TJ
    Mol Cancer Res; 2009 Sep; 7(9):1477-86. PubMed ID: 19737967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes.
    Pattabiraman DR; McGirr C; Shakhbazov K; Barbier V; Krishnan K; Mukhopadhyay P; Hawthorne P; Trezise A; Ding J; Grimmond SM; Papathanasiou P; Alexander WS; Perkins AC; Levesque JP; Winkler IG; Gonda TJ
    Blood; 2014 Apr; 123(17):2682-90. PubMed ID: 24596419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A synthetic covalent ligand of the C/EBPβ transactivation domain inhibits acute myeloid leukemia cells.
    Abdel Ghani L; Yusenko MV; Frank D; Moorthy R; Widen JC; Dörner W; Khandanpour C; Harki DA; Klempnauer KH
    Cancer Lett; 2022 Apr; 530():170-180. PubMed ID: 35077804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells.
    Klempnauer KH
    Oncotarget; 2023 Mar; 14():174-177. PubMed ID: 36913305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptidomimetic blockade of MYB in acute myeloid leukemia.
    Ramaswamy K; Forbes L; Minuesa G; Gindin T; Brown F; Kharas MG; Krivtsov AV; Armstrong SA; Still E; de Stanchina E; Knoechel B; Koche R; Kentsis A
    Nat Commun; 2018 Jan; 9(1):110. PubMed ID: 29317678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Convergent organization of aberrant MYB complex controls oncogenic gene expression in acute myeloid leukemia.
    Takao S; Forbes L; Uni M; Cheng S; Pineda JMB; Tarumoto Y; Cifani P; Minuesa G; Chen C; Kharas MG; Bradley RK; Vakoc CR; Koche RP; Kentsis A
    Elife; 2021 Feb; 10():. PubMed ID: 33527899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb by Blocking the Interaction with the KIX Domain of the Coactivator p300.
    Uttarkar S; Dukare S; Bopp B; Goblirsch M; Jose J; Klempnauer KH
    Mol Cancer Ther; 2015 Jun; 14(6):1276-85. PubMed ID: 25740244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic activation of the human choline acetyltransferase gene by c-Myb and C/EBPbeta.
    Robert I; Sutter A; Quirin-Stricker C
    Brain Res Mol Brain Res; 2002 Oct; 106(1-2):124-35. PubMed ID: 12393272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structures of KIX domain of CBP in complex with two FOXO3a transactivation domains reveal promiscuity and plasticity in coactivator recruitment.
    Wang F; Marshall CB; Yamamoto K; Li GY; Gasmi-Seabrook GM; Okada H; Mak TW; Ikura M
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6078-83. PubMed ID: 22474372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. v-Myc inhibits C/EBPbeta activity by preventing C/EBPbeta-induced phosphorylation of the co-activator p300.
    Steinmann S; Schulte K; Beck K; Chachra S; Bujnicki T; Klempnauer KH
    Oncogene; 2009 Jul; 28(26):2446-55. PubMed ID: 19448669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A conserved patch of hydrophobic amino acids modulates Myb activity by mediating protein-protein interactions.
    Dukare S; Klempnauer KH
    Biochim Biophys Acta; 2016 Jul; 1859(7):914-21. PubMed ID: 27080133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner.
    Yusenko MV; Biyanee A; Andersson MK; Radetzki S; von Kries JP; Stenman G; Klempnauer KH
    Cancer Lett; 2021 Nov; 520():132-142. PubMed ID: 34256093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.